1 results match your criteria: "3 STZ eyetrial at the Centre for Ophthalmology[Affiliation]"
Development of Methodology and Study Protocol: Safety and Efficacy of a Single Subretinal Injection of rAAV.hCNGA3 in Patients with CNGA3-Linked Achromatopsia Investigated in an Exploratory Dose-Escalation Trial.
Hum Gene Ther Clin Dev
September 2018
3 STZ eyetrial at the Centre for Ophthalmology, Tuebingen, Germany .
Article Synopsis
- * In a clinical study, patients received a single subretinal injection of a gene therapy (rAAV.hCNGA3) aimed at restoring the function of these cone photoreceptors.
- * The study primarily evaluated the safety of this treatment through a series of eight visits in the first year and annual follow-ups over four years, using specialized methods to assess outcomes.